Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health systemShow full item record
Title | Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system |
---|---|
Author | Lu Y.; Gehr A.W.; Meadows R.J.; Ghabach B.; Neerukonda L.; Narra K.; Ojha R.P. |
Date | 2022 |
Abstract | Background: Prior studies reported survival benefits from early initiation of adjuvant chemotherapy for stage III colon cancer, but this evidence was derived from studies that may be sensitive to time-related biases. Therefore, we aimed to estimate the effect of initiating adjuvant chemotherapy ?8 or ? 12 weeks on overall and disease-free survival among stage III colon cancer patients using a study design that helps address time-related biases. Methods: We used institutional registry data from JPS Oncology and Infusion Center, a Comprehensive Community Cancer Program. Eligible patients were adults aged < 80 years, diagnosed with first primary stage III colon cancer between 2011 and 2017, and received surgical resection with curative intent. We emulated a target trial with sequential eligibility. We subsequently pooled the trials and estimated risk ratios (RRs) along with 95% confidence limits (CL) for all-cause mortality and recurrence or death at 5-years between initiators and non-initiators of adjuvant chemotherapy ?8 or ? 12 weeks using pseudo-observations and a marginal structural model with stabilized inverse probability of treatment weights. Results: Our study population comprised 222 (for assessing initiation ?8 weeks) and 310 (for assessing initiation ?12 weeks) observations, of whom the majority were racial/ethnic minorities (64–65%), or uninsured with or without enrollment in our hospital-based medical assistance program (68–71%). Initiation of adjuvant chemotherapy ?8 weeks of surgical resection did not improve overall survival (RR for all-cause mortality = 1.04, 95% CL: 0.57, 1.92) or disease-free survival (RR for recurrence or death = 1.07, 95% CL: 0.61, 1.88). The results were similar for initiation of adjuvant chemotherapy ?12 weeks of surgical resection. Conclusions: Our results suggest that the overall and disease-free survival benefits of initiating adjuvant chemotherapy ?8 or ? 12 weeks of surgical resection may be overestimated in prior studies, which may be attributable to time-related biases. Nevertheless, our estimates were imprecise and differences in population characteristics are an alternate explanation. Additional studies that address time-related biases are needed to clarify our findings. © 2022, The Author(s). |
Link | https://doi.org/10.1186/s12885-022-09688-w
https://repository.tcu.edu/handle/116099117/55834 |
Department | Burnett School of Medicine |
Subject | Adjuvant chemotherapy
colon cancer Disease-free survival Mortality Prognosis Quality of care Timing |
Files in this item
This item appears in the following Collection(s)
- Research Publications [1008]
© TCU Library 2015 | Contact Special Collections |
HTML Sitemap